Clarivate for Life Sciences & Healthcare’s Post

🌟Navigating the UAE Pharmaceutical Terrain 🌟   Operating a pharmaceutical business in the UAE presents a unique set of challenges, from navigating regulatory frameworks to understanding consumer behavior. Morphosis specializes in guiding clients through this intricate terrain, providing strategic insights and meticulous planning to ensure seamless execution. With a deep understanding of the local landscape, Morphosis empowers brands to overcome obstacles and thrive in a competitive market. 🔊 Morphosis, a pioneering marketing firm led by industry veterans Muhammad Usman Qaiser and Rija Nawab. With a wealth of experience spanning both the UAE and Pakistan’s pharmaceutical markets, Morphosis is redefining how brands connect and thrive in the competitive healthcare landscape of the UAE. Read the complete Article about Morphosis: https://lnkd.in/dANbkbwm #BusinessinUAE, #healthnews, #MarketingServices, #pharmaceuticalsinUAE, #PharmaUAE, #UAE

🔒 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗦𝗮𝘂𝗱𝗶 𝗔𝗿𝗮𝗯𝗶𝗮𝗻 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗠𝗮𝗿𝗸𝗲𝘁: 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗮𝗻𝗱 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀🔒 As pharmaceutical companies look to expand their global footprint, Saudi Arabia is becoming an increasingly attractive option, serving as a gateway to the Middle Eastern and North African markets. At Inbeeo, we appreciate that aligning with the Saudi Arabia’s vision2030 and navigating reimbursement pathways will be critical to successful launches in this market. 🌟 𝗩𝗶𝘀𝗶𝗼𝗻 𝟮𝟬𝟯𝟬 𝗮𝗻𝗱 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁: Saudi Arabia’s Vision 2030 plan allocates significant resources to healthcare, focusing on enhancing service access, improving quality, and strengthening preventive measures. This initiative presents an opportunity for pharmaceutical companies to align their strategies with national goals regarding improving healthcare. 🏥 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁 𝗣𝗮𝘁𝗵𝘄𝗮𝘆𝘀: •   𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗦𝗲𝗰𝘁𝗼𝗿: Price and registration are often sufficient for access, with individual hospitals requesting additional data. •   𝗣𝗮𝗿𝗮𝗹𝗹𝗲𝗹 𝘁𝗼 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝘂𝘁𝗵𝗼𝗿𝗶𝘀𝗮𝘁𝗶𝗼𝗻: Early reimbursement and physician engagement can raise product profiles and increase uptake through patient access programmes. •   𝗠𝗶𝗻𝗶𝘀𝘁𝗿𝘆 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵 (𝗠𝗼𝗛) 𝗖𝗲𝗻𝘁𝗿𝗮𝗹 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁: National access is granted through the engagement of the MoH stakeholders, with regional Pharmacy and Therapeutic Committees (P&TCs) evaluating clinical and economic data, leading to the inclusion of the product on the Saudi National Formulary. 📊 𝗨𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗲𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗚𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀: •   𝗟𝗮𝘂𝗻𝗰𝗵𝗶𝗻𝗴 𝗶𝗻 𝟮𝟬𝟮𝟱: These guidelines will mandate the submission of cost and budget impact analyses, with decisions from other influential HTA bodies playing a significant role. •   𝗖𝗼𝘀𝘁-𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀 𝘁𝗵𝗿𝗲𝘀𝗵𝗼𝗹𝗱𝘀: SAR 50k-75k (equating to ~£10k-15,500) will be implemented from 2025. Saudi Arabia's strategic initiatives and evolving reimbursement pathways offer a viable opportunity for broadening access to innovative treatment options. By fully understanding the objectives and mechanisms linked to vision2030, companies can navigate the complexities of the market and achieve sustainable success. Written by Katie Hill, our Senior Associate Here at Inbeeo, we can support companies with aligning and developing their launch strategies for Saudi Arabia, with further adaptation to the MENA region. Contact us today! #Pharmaceuticals #Healthcare #SaudiArabia #Vision2030 #MarketEntry #HealthcareInnovation #PharmaGrowth

Did you know the pharmaceutical market in #SaudiArabia is growing rapidly, and is expected to reach $11.5 billion by 2032. Factors driving growth include: Government investment in healthcare infrastructure  Rising healthcare expenditure  Collaborations between local and international pharmaceutical companies  Medical tourism  I am delighted to be attending CPHI Middle East 8th-10th December. #Connect with me to hear how Sterling Bell Leadership advisory is on the ground in #Riydah, providing solutions including #leadershipprogrammes, #assessments in addition to #executiverecruitment in the #pharmaceutical and #heathcare sectors.  

The collaboration between AVALON Pharma and Al-Dawaa Medical Services Co. (DMSCO) to locally manufacture essential medications is a game-changer. By ensuring a secure and affordable #supplychain, this partnership will greatly reduce dependence on external sources and help prevent medication shortages. Not only does this initiative promise high-quality medications at competitive prices, but it also significantly strengthens our healthcare infrastructure and contributes to #economicdevelopment through job creation. It's a crucial step toward a more resilient and prosperous healthcare system in Saudi Arabia. I'm curious, what steps can other countries take to boost local drug manufacturing? Let's discuss! #SaudiArabia #AvalonPharma #DMSCO #SaudiVision2030 #PatientAccess #Localization #LocalManufacturing #AffordableDrugs #CompetitivePricing #HealthcareInfrastructure #GulfCountries #MENA #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

We are honored to introduce the third group of distinguished speakers who will enrich our discussions at this landmark event. These leaders are driving innovation and transformation across healthcare, pharmaceuticals, and digital technology in the region: 1️⃣ Dr. Gamal El-Leithy Chairman & CEO, Future Pharmaceutical Industries (FPi) | Head, Pharmaceutical Chamber, Federation of Egyptian Industries – Shaping the future of pharmaceutical innovation and industry leadership. 2️⃣ Prof. Dr. Aiman S. El Khatieb Vice President, Egyptian Drug Authority – Enhancing regulatory frameworks for pharmaceutical excellence and innovation. 3️⃣ Eng. Mahmoud Badawi Advisor to the Minister on Digital Transformation Affairs, Ministry of Communications and Information Technology (MCIT), Egypt – Pioneering digital transformation in healthcare for a more connected and efficient system. 4️⃣ Dr. Hesham Badr Vice President, Egyptian Authority for Unified Procurement, Medical Supply, and Technology Management – Streamlining healthcare procurement for better access and efficiency. These speakers will explore pivotal themes, including innovations in pharmaceutical manufacturing, the impact of digital transformation on healthcare delivery, and strategies for enhancing access to medical technologies through unified procurement frameworks. 📅 Join us on December 14, 2024, for the ACCESS Health MENA Contemporary Healthcare Dialogues, where thought leaders and practitioners come together to redefine healthcare for the region. 📍 Cairo, Egypt | Livestream link in the comments #HealthcareInnovation #DigitalTransformation #PharmaceuticalLeadership #MENAHealthcare #GlobalHealthSystems

As Arab Health 2025 approaches, we would like to connect for future expansion. So,Symbiosis group of pharma companies invites you to visit us to explore more for further potential collaboration. #arabhealth2025 #informa #pharma #dubai2025

Great news for Saudi Healthcare! AVALON Pharma, a leading local player, has partnered with Al-Dawaa Medical Services Co. (DMSCO) to manufacture essential medications. This collaboration aims to create a secure and affordable #supplychain for Saudi patients. By producing drugs locally, the agreement reduces dependence on external sources and minimizes medication shortages. Additionally, Avalon Pharma and DMSCO prioritize offering high-quality medications at competitive prices, making them more accessible for citizens. This initiative not only strengthens Saudi Arabia's healthcare infrastructure but also contributes to the nation's #economicdevelopment through job creation. Avalon Pharma sees this as a crucial step towards a more secure and prosperous healthcare system for Saudi Arabia. What can other countries do to encourage local drug manufacturing? Let's discuss! #SaudiArabia #AvalonPharma #DMSCO #SaudiVision2030 #PatientAccess #Localization #LocalManufacturing #AffordableDrugs #CompetitivePricing #HealthcareInfrastructure #SaudiArabia #GulfCountruies #MENA #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification Detailed News: https://lnkd.in/dHk2jYxW Follow our page for more industry updates: https://lnkd.in/de5zNWmK

🥳 Welcome Marco Antonio Fernandes, Business Development Manager at Bionovis as a panelist in the Biosimilars LatAm - Brazil 2024 Forum!  Marco Antonio Fernandes will share his extensive experience on how Brazil's unique regulatory landscape compares to the FDA and European Medicines Agency, exploring opportunities to accelerate licensing and leveraging regulatory knowledge as a competitive tool. 🗓️ Date: August 21-22, 2024  📍 Venue: Pullman Ibirapuera São Paulo Hotel Discover new perspectives and build valuable connections with professionals in the field!  Join our event to gain useful knowledge and engage in dynamic debates at Biosimilars LatAm - Brazil 2024 💡 Register now: https://lnkd.in/d5RTHdk2 If you are affiliated with any of the following organizations, please contact us for a discount code: 🤝 ABIFINA, ABIQUIFI, ABRACRO, Alianza de CROs de Mexico (ACROM) , ALANAC - Associação dos Laboratórios Farmacêuticos Nacionais, AMELAF, Amepres México, CANIFARMA, CAPGEN - Cámara Argentina de Productores de Medicamentos Hospitalarios, IGBA - International Generic and Biosimilar medicines Association, PróGenéricos, SINDIFARGO, União Farmacêutica de São Paulo - UNIFAR #BiosimilarsForum #Brazil2024 #RegulatoryInsights #Biopharma #MarketOpportunities 

🌍 Join Us in Transforming Healthcare Access in Africa 🌍 At MedNord AB, we’re driven by a powerful vision: making high-quality, affordable healthcare accessible across Africa. With our robust distribution network and established partnerships in the region, we’re ready to help pharmaceutical companies reach new, high-demand markets. Why Partner with MedNord AB? Extensive Market Reach: Our deep local insights and established partnerships enable smooth, scalable entry into diverse African regions. Rapid Growth Potential: The demand for essential medications, chronic disease treatments, and innovative therapies is rising across the continent. Proven Expertise: From navigating regulatory requirements to providing efficient distribution, we have the know-how to support successful market expansion. We’re seeking pharmaceutical companies and healthcare innovators eager to make a difference and expand their global reach. If your company is ready to seize the opportunity of tapping into Africa’s growing healthcare market, let’s collaborate. 🤝 Ready to take the next step? Partner with MedNord AB to expand your reach and bring transformative healthcare solutions to the African market. Let’s explore how we can make a powerful impact together. #HealthcareInnovation #PharmaceuticalPartnership #GlobalExpansion #MedNordAB

Health Technology Assessment Unites Nordic Countries: Formation of Joint Nordic HTA-Bodies The formation of the Joint Nordic HTA-Bodies (JNHB) marks a significant advancement in health technology assessment (HTA) collaboration in the Nordic region, now including Denmark and Iceland alongside Finland, Norway, and Sweden. To celebrate, JNHB invited industry associations, decision-makers, and stakeholders to a launch event unveiling their new website, which provides detailed guidance for Health Technology Developers. Initially a grassroots initiative, FINOSE expanded and rebranded to JNHB, formalized through a Memorandum of Understanding signed by the Lægemiddelstyrelsen (Danish Medicines Agency), Finnish Medicines Agency Fimea - Lääkealan turvallisuus- ja kehittämiskeskus Fimea, Landspítali - The National University Hospital of Iceland, Norwegian Medical Products Agency, and Swedish The Dental and Pharmaceutical Benefits Agency, TLV. For more details please click the link! https://lnkd.in/eUKmdp_a #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical